FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH.
Boehringer Ingelheim’s focus on the development of next generation NASH treatments builds on its strong track record of bringing new therapies to people with cardiometabolic diseases.
INGELHEIM, Germany & COPENHAGEN, Denmark -- (BUSINESS WIRE) --
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH). The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis (F2/F3) with and without diabetes.
“The FDA Fast Track Designation for our dual agonist is an important step forward in addressing the high unmet medical need among the up to 444 million adults estimated to be living with NASH,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “Together with our partner Zealand Pharma, we look forward to working closely with the FDA as we explore the potential of the GLP-1/glucagon agonist to improve outcomes for adults with NASH.”
“Boehringer Ingelheim and Zealand Pharma are committed to delivering innovative solutions that address public health challenges of cardiometabolic diseases, including NASH,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “By combining Boehringer Ingelheim’s expertise in drug development in the cardio-metabolic area with our strength in the discovery of innovative peptide-based medicines, we have the potential to bring forward a novel therapy option in an area with limited available treatments.”
The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. It is also being investigated as a potential treatment option for adults living with diabetes and for adults living with obesity. It is part of Boehringer Ingelheim’s research and development portfolio in the cardiometabolic disease areas.
世界读书日临近 亲子阅读成全民阅读重头戏
Elastic任命Barrie Sheers为亚太及日
雅诗兰黛公司宣布Jane Lauder将被任命为企业营销
诸城市非物质文化遗产“赶大集”活动 在金查
企业元宇宙:员工已准备就绪,组织能否跟上
Intelsat向史密森国家航空航天博物馆捐赠
Sims Limited获选为“2023年亚太区气候领袖”
江西省抚州市委宣传部考察团深入上饶市信州区
Alchemab入选NVIDIA项目,将利用剑桥1号
E和GVK BIO宣布战略研发伙伴关系
NTT:签订国际热核聚变实验堆(ITER)合作协议
Q3医疗器械有限公司与美敦力签署生物可降解胆
Monde Nissin Complete
第八届“艺庐雅集”在中国美术导报艺术交流基
泰雷兹和塔塔通信联手解决企业面临的物联网数
Engine Biosciences宣布获得超额认购
斯伦贝谢公布2021年第三季度财务业绩
在野泽温泉体验真诚的健康关怀:通过中长期住
迪进国际推出Digi XBee RR模块和快速重新设计服务
平度市人民法院召开“无讼村庄(社区)”创建
北京捷越凭实力出圈荣获“2019卓越竞争力金融
疫情就是命令,防控就是责任,庆云县委党史研
北京五棵松:你记忆中的后备箱夜市,来了!
Northleaf Infrastructure C